chronic Hepatitis B
Conditions
Interventions
Treatment group:nucleos(t)ide analogues treatment
Control group:no nucleos(t)ide analogues therapy
Sponsors
West China Hospital of Sichuan University
Eligibility
Sex/Gender
All
Age
18 Years to 75 Years
Inclusion criteria
Inclusion criteria: 1. Detectable hepatitis B surface antigen (HBsAg) levels for at least 6 months, undetectable HBeAg and detectable HBeAb before screening; 2. At least three ALT values less than the upper limit of normal range within one year that were at least 3 months apart (the upper limits of normal ALT were 50U/L for male and 40U/L for female, respectively); 3. Detectable HBV DNA (>= 20 IU/mL); 4. No signs of cirrhosis or liver nodules by liver ultrasound; 5. HBV treatment na?ve, including NAs or interferon; 6 .Volunteering to participate in the study and commit to cooperate with the completion of follow-up.
Exclusion criteria
Exclusion criteria: 1. Pregnant women; 2. Age < 18; 3. Coinfection with HIV, HCV, or HDV; 4. Suffered from other forms of liver disease, for example, alcoholic, autoimmune or biliary disease; 5. Confirmed diagnosis of liver cirrhosis, primary liver cancer or liver metastasis.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| loads of serum HBV DNA;loads of serum HBV RNA;quality of life; | — |
Secondary
| Measure | Time frame |
|---|---|
| live nodules;liver stiffness;hepatocellular carcinoma (HCC); | — |
Countries
China
Contacts
Public ContactEnqiang Chen
West China Hospital of Sichuan University
Outcome results
None listed